420 with PNW – Four Science-Backed Potential Medical Uses of Psychedelic Products

June 17, 2020 03:25:00

If you are wondering why Denver (Colorado), Santa Cruz and Oakland (California), as well as other cities are about to or have actually decriminalized psychedelics, also referred to as entheogenic plants, wonder no more. These plants have numerous potential therapeutic uses as the following analysis will show.

Substance Dependency

Isn’t it such an interesting irony that plants which are lumped together among dangerous substances are now being found to hold the key to help people overcome their addiction to various substances?

Research suggests that a number of psychedelics including LSD, ibogaine, peyote and ayahuasca can help people beat addiction and dependency on drugs. The findings point to the possibility that psychedelics work to break addiction by interacting with serotonin pathways and systems in order to aid substance cessation. This could explain the physical, cognitive, psychological and mental shifts addicts undergo once they are treated with entheogenic plants.


The traditional approach to managing post-traumatic stress disorder often includes psychotherapy, and sufferers can have PTSD triggers activated, thereby causing the person to have full-blown symptoms of the condition.

Studies show that switching to psychedelics in combination with psychotherapy helps patients recall traumatic experiences without experiencing the accompanying negative feelings that those memories bring up. Additionally, research shows that just 2 or 3 sessions were sufficient to trigger improvements in the patients, unlike conventional approaches that take months or even years before yielding results, if any.

Depression and Anxiety

Millions of people suffer from depression and anxiety in the U.S., and these figures are likely to get a whole lot higher in the aftermath of the COVID-19 crisis. To make matters worse, a significant proportion of patients are unresponsive to the current medications for depression and anxiety.

Fortunately, research dating back to the 1950s funded by the National Institute of Mental Health shows that MDMA, psilocybin and other substances in this category have the potential to improve symptoms among people with treatment-resistant forms of depression and anxiety. The transformative shift that patients undergo lasts a lot longer than can ever be achieved by the conventional remedies, the research adds.

Obsessive Compulsive Disorder

The quality of life of patients with OCD is severely compromised by this condition and yet many of the patients are unable to find relief when they undergo the existing treatment regimes.

However, studies indicate that patients treated with psychedelics like psilocybin experience fewer symptoms and are psychologically as well as spiritually enriched. This is especially true of patients with treatment-resistant forms of OCD.

While research into psychedelics is still in its infancy, the possibilities for their use are so profound that it isn’t surprising that companies like ATAI Life Sciences AG are investing lots of resources into research and development so that the therapeutic potential of psychedelics can be tapped.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a far-out information destination focused on (1) delivering the freshest headlines on psychedelics and ‘shrooms, (2) issuing PsychedelicNewsBreaks that are specially crafted to keep the grooviest investors in-the-know, (3) laying down the choicest enhancements for corporate news releases, (4) doing our public and private client-partners a solid with full-service distribution and social media services and (5) taking custom-built corporate communication solutions to the max. PNW has a totally awesome spot in the booming psychedelics space, and our ace team of journalists is always grinding to help our growing roster of clients reach a sizable audience of investors, consumers and media outlets. We’ve got a network of more than 5,000 key syndication outlets to help you deliver dy-no-mite visibility, recognition and content within the psychedelic industry. PsychedelicNewsWire (PNW) is where PSYCHEDELIC news, content and information converge.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.